Adrenergic regulation of cancer immunity

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract The nervous and immune systems engage in extensive bidirectional crosstalk that shapes tumor progression and therapeutic response. Among the neuro-immune pathways involved in cancer, adrenergic receptor signaling has emerged as a key regulator of the tumor microenvironment. In this review, we summarize current understanding of the distinct roles of β- and α2-adrenergic receptor signaling in cancer immunity and their therapeutic implications. β2-adrenergic receptor signaling promotes immune suppression by impairing dendritic cell cross-presentation, inhibiting CD8⁺ T cell and natural killer (NK) cell function, driving T cell exhaustion, and enhancing regulatory T cell and myeloid-derived suppressor cell activity. Consistent with these mechanisms, retrospective studies and meta-analyses involving more than 600,000 patients have associated β-blocker use with survival benefits in several cancers. In contrast, recent preclinical studies demonstrate that α2-adrenergic receptor agonists induce potent anti-tumor immunity in immunocompetent murine models, including checkpoint-resistant tumors, through CD4⁺ and CD8⁺ T cell-dependent mechanisms. Together, these findings identify adrenergic signaling as a promising and pharmacologically tractable target in cancer immunotherapy and support further translational and clinical investigation.